

Vaxxas opens manufacturing facility in Australia to produce needle-free vaccine patch

19 June 2023 | News

Company expects to grow to 200 employees in the next three to five years

Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform technology, has announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland.

The custom-built 5,500 square meter (60,000 square feet) Vaxxas Biomedical Facility will serve as the company's global headquarters and support the scale-up of its operations to produce HD-MAP vaccines for future late-stage clinical trials and first commercial products.

The Queensland Government provided funding and operational support to Vaxxas in developing the facility. Vaxxas has received additional funding from the Australian Government through its Modern Manufacturing Initiative to support the installation of specialised manufacturing and production infrastructure. The facility represents a significant investment in the future of Queensland's and Australia's biotech sectors.

Vaxxas' proprietary HD-MAP technology platform has the potential to improve vaccination by creating vaccine products that are easy to use (potentially enabling self-administration) and can be stable at room temperature, reducing the complexities and costs associated with refrigerated distribution required for many existing vaccines.

Vaxxas currently employs 130 people in its Queensland operations, and is planning for an increase to 200 employees over the next three to five years. The new facility will enable Vaxxas' R&D teams to work side by side with manufacturing teams, to expand existing R&D work and streamline the translation from research to eventual commercialization.